FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Recently, the neonatal Fc receptor (FcRn) inhibitor efgartigimod has demonstrated clinically proven efficacy in a phase III trial and has been approved for the treatment of CIDP [3], thereby expanding the range of available therapeutic options.